ProKidney Corp. (PROK) Key Metrics
PROK valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $530.9M
- Enterprise value
- $204.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 649.0
- Price / book
- 97.2
- EV / EBITDA
- 2.1
- Dividend yield
- —
- Beta
- 1.80
PROK key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPROK valuation Price multiples at each fiscal year-end price.
Free cash flow yield+49.1 pts
−45.1%
2025 · hover or tap a bar for each year
20192025
PROK returns How much profit the business earns on the capital it uses.
Return on assets−3.6 pts
−17.8%
2025 · hover or tap a bar for each year
20192025
Asset turnover+1,203.6%
0.00
2025 · hover or tap a bar for each year
20192025
PROK per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+759.0%
$0.01
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.52
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$1.01
2025 · hover or tap a bar for each year
20192025
Book value per share
−$7.55
2025 · hover or tap a bar for each year
20192025
Shares outstanding+36.8%
133.9M
2025 · hover or tap a bar for each year
20192025
PROK financial health Debt, liquidity and how easily interest is covered.
Net debt+$89.1M
−$266.0M
2025 · hover or tap a bar for each year
20192025
Current ratio−16.5%
9.13
2025 · hover or tap a bar for each year
20192025
Debt / assets+63.9%
0.01
2025 · hover or tap a bar for each year
20192025
PROK efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−8,447 days
730 days
2025 · hover or tap a bar for each year
20192025
Days payables outstanding
146 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue−37,126.0 pts
1,701.7%
2025 · hover or tap a bar for each year
20192025
PROK valuation history
Fiscal year-endToday7-year median
PROK returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PROK debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PROK cash returned to shareholders
DividendsBuybacksFree cash flow
PROK price vs earnings per share
Share price at year-endEPS (right axis)
PROK key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $300.0M | $165.5M | $109.9M | $422.2M | — | — | — |
| Enterprise value | $34.1M | −$189.6M | −$248.7M | −$65.7M | — | — | — |
| Price / sales | 336.0 | — | — | — | — | — | — |
| EV / sales | 38.1 | -2,494.4 | — | — | — | — | — |
| Earnings yield | −23.0% | −37.0% | −32.3% | −25.6% | — | — | — |
| Free cash flow yield | −45.1% | −94.2% | −113.1% | −18.7% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 8.6% | 0.0% | — | — | — |
| Share price at fiscal year-end | $2.24 | $1.69 | $1.78 | $6.86 | $9.90 | — | — |
| Per share | |||||||
| Revenue per share | $0.01 | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Earnings per share | −$0.52 | −$0.62 | −$0.57 | −$1.76 | — | −$0.14 | −$1.01 |
| Operating cash flow per share | −$0.90 | −$1.29 | −$1.46 | −$1.25 | — | −$0.14 | −$0.00 |
| Free cash flow per share | −$1.01 | −$1.59 | −$2.01 | −$1.28 | — | −$0.16 | −$0.00 |
| Cash per share | $2.02 | $3.66 | $5.88 | $7.97 | — | $0.02 | $0.19 |
| Book value per share | −$7.55 | −$10.16 | −$17.88 | −$17.82 | — | $0.05 | $0.20 |
| Tangible book value per share | −$7.55 | −$10.16 | −$17.88 | −$17.82 | — | $0.05 | $0.19 |
| Capex per share | $0.11 | $0.30 | $0.55 | $0.03 | — | $0.03 | $0.00 |
| Debt per share | $0.03 | $0.03 | $0.07 | $0.04 | — | $0.01 | $0.01 |
| Shares outstanding | 133.9M | 97.9M | 61.7M | 61.5M | — | 186.5M | 78.5M |
| Change in shares outstanding | +36.8% | +58.7% | +0.3% | — | — | +137.5% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | — | — | — | — | −299.9% | −207.8% | −501.3% |
| Return on invested capital (ROIC) | — | — | — | — | −598.9% | −495.7% | — |
| Return on assets (ROA) | −17.8% | −14.2% | −7.6% | −38.7% | −193.5% | −147.3% | −406.1% |
| Return on tangible assets | −20.6% | −13.9% | −8.4% | −20.9% | −139.8% | −166.6% | −424.6% |
| Financial health | |||||||
| Total debt | $4.0M | $3.2M | $4.4M | $2.4M | $1.3M | $1.6M | $1.1M |
| Cash & short-term investments | $270.0M | $358.3M | $362.9M | $490.3M | $20.6M | $4.6M | $15.2M |
| Net debt | −$266.0M | −$355.1M | −$358.5M | −$487.9M | −$19.2M | −$3.0M | −$14.1M |
| Debt / equity | — | — | — | — | 0.05 | 0.16 | 0.07 |
| Debt / assets | 0.01 | 0.01 | 0.01 | 0.00 | 0.03 | 0.09 | 0.06 |
| Current ratio | 9.13 | 10.93 | 14.94 | 46.42 | 2.21 | 1.02 | 5.68 |
| Quick ratio | 9.13 | 10.93 | 14.94 | 46.42 | 2.21 | 1.02 | 5.68 |
| Interest coverage | — | — | — | -711.7 | — | -628.5 | — |
| Working capital | $249.9M | $359.7M | $349.1M | $493.8M | $15.0M | $83,000 | $12.7M |
| Invested capital | −$1.28B | −$1.35B | −$1.46B | −$1.58B | $7.7M | $6.8M | $1.8M |
| Tangible asset value | $300.8M | $401.6M | $391.3M | $504.7M | $26.1M | $9.2M | $15.0M |
| Net current asset value | $245.9M | $356.4M | $344.9M | $491.7M | $13.9M | −$1.3M | $11.7M |
| Graham net-net per share | $1.76 | $3.28 | $5.42 | $7.75 | — | −$0.01 | $0.15 |
| Capital allocation | |||||||
| Share buybacks (net) | $0 | $0 | $9.5M | $0 | $0 | — | — |
| Capex / revenue | 1,701.7% | 38,827.6% | — | — | — | — | — |
| Capex / depreciation | 2.31 | 5.43 | 8.88 | 0.61 | 2.62 | 5.66 | 1.51 |
| Stock-based compensation / revenue | 2,837.2% | 38,647.4% | — | — | — | — | — |
| R&D / revenue | 12,779.7% | 167,984.2% | — | — | — | — | — |
| SG&A / revenue | 5,798.1% | 73,794.7% | — | — | — | — | — |
| Efficiency | |||||||
| Days sales outstanding | 730.4 | 9,177.8 | — | — | — | — | — |
| Days payables outstanding | 145.9 | — | 468.9 | 353.3 | 332.5 | — | — |
| Cash conversion cycle (days) | 584.6 | — | — | — | — | — | — |
| Receivables turnover | 0.50 | 0.04 | 0.00 | — | — | — | — |
| Payables turnover | 2.50 | 0.00 | 0.78 | 1.03 | 1.10 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.8M | $1.9M | $1.4M | — | — | — | — |
| Average payables | $2.3M | $4.4M | $4.1M | $2.9M | $1.8M | $630,500 | $480,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% | 3.8% | 4.4% |
Computed from PROK's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PROK valuation and financial ratios
It ended the year with $4.0 million of debt and $270.0 million in cash and short-term investments, a net cash position of $266.0 million. The share count rose 70.6% from 78.5M to 133.9M over 6 years.
See the PROK income statement, the PROK chart for price history, or the PROK stock overview for the latest quote and news.
PROK key metrics FAQ
How much debt does ProKidney have?
ProKidney had total debt of $4.0 million at the end of fiscal 2025 and more cash than debt.
What is ProKidney's free cash flow yield?
ProKidney generated -$135.3 million of free cash flow in fiscal 2025, a free cash flow yield of −45.1% on its market value at year-end ($300.0 million).
What is ProKidney's current ratio?
ProKidney's current ratio was 9.13 at the end of fiscal 2025: current assets were 9.13 times current liabilities.